Compare Mesoblast Limited (MESO) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs State Street PDR S&P Retail ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while State Street PDR S&P Retail ETF trades at $86.52 (market cap $389.66M). The key difference: Mesoblast Limited is far larger — about 4.5× State Street PDR S&P Retail ETF's market cap, and State Street PDR S&P Retail ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| MESO | XRT | |
|---|---|---|
Market Cap | $1.75B | $389.66M |
Volume | 239,027 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $20.96 | $92.35 |
52-Week Low | $13.19 | $77.28 |
Typical Hold Time | 14 Days | 44 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
XRT (SPDR S&P Retail ETF) trades at $82.91, showing minimal daily movement with a slight decline of 0.05%. Technical indicators signal a bearish trend overall, with moving averages particularly negative. The ETF faces headwinds from higher interest rates and inflation impacting consumer spending, though recent retail sales data showed a strong August rebound. Analyst sentiment remains cautious with expectations of continued underperformance against broader market indices.
The retail sector faces macroeconomic pressures including inflation and rising rates that weigh on consumer discretionary spending. While holiday sales projections exceed $1 trillion, selective consumer behavior favors value-oriented retailers. Near-term performance depends on Fed policy direction and consumer resilience during the critical holiday season, with technical resistance at $83-$84 levels limiting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
